Oragenics to Acquire Odyssey Health's Neurological Drug Technology Pipeline Including Concussion Drug Candidate

Stock Information for Odyssey Group Intl Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Odyssey Group Intl Inc

Odyssey Health, Inc. Strengthens Balance Sheet with $8.7 Million in Net Equity
Odyssey Health Closes Asset Sale of its Neurological Drug Technology Pipeline Including Concussion Drug Candidate with Oragenics, Inc.
Odyssey Health, Inc, Selects Syneos Health to Support Investigational New Drug Application for Treatment of Concussion
Odyssey Health, Inc. to Provide Company Update and Webcast for Shareholders
Odyssey Health, Inc. Provides Update on Asset Purchase Agreement with Oragenics, Inc.
Odyssey Health Inc. Begins Trading on the OTCQB
Odyssey Health, Inc. Presents Concussion Treatment Data at the Military Health System Research Symposium - MHSRS
Odyssey Health, Inc. Presents Data at the Special Operations Medical Association - Scientific Assembly

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.